LQDA

NASDAQ

Liquidia Corporation

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2018

$37.32-0.20 (-0.53%)

News25/Ratings12

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Price$37.32+0.28 (+0.76%)

01:30 PM07:45 PM

News · 26 weeks92+30%

2025-10-262026-04-19

Mix5290d

Insider28(54%)
SEC Filings19(37%)
Other5(10%)

Latest news

25 items

10hSEC
SEC Form DEFA14A filed by Liquidia Corporation
DEFA14A - Liquidia Corp (0001819576) (Filer)
10hSEC
SEC Form DEF 14A filed by Liquidia Corporation
DEF 14A - Liquidia Corp (0001819576) (Filer)
3dINSIDER
SEC Form 4 filed by Jeffs Roger
4 - Liquidia Corp (0001819576) (Issuer)
7dSEC
SEC Form 144 filed by Liquidia Corporation
144 - Liquidia Corp (0001819576) (Subject)
8dINSIDER
SEC Form 4 filed by Jeffs Roger
4 - Liquidia Corp (0001819576) (Issuer)
8dINSIDER
SEC Form 4 filed by Kaseta Michael
4 - Liquidia Corp (0001819576) (Issuer)
8dSEC
SEC Form 144 filed by Liquidia Corporation
144 - Liquidia Corp (0001819576) (Subject)
9dSEC
SEC Form 144 filed by Liquidia Corporation
144 - Liquidia Corp (0001819576) (Subject)
9dSEC
SEC Form 144 filed by Liquidia Corporation
144 - Liquidia Corp (0001819576) (Subject)
10dINSIDER
SEC Form 4 filed by Moomaw Scott
4 - Liquidia Corp (0001819576) (Issuer)
10dINSIDER
SEC Form 4 filed by Adair Jason
4 - Liquidia Corp (0001819576) (Issuer)
10dINSIDER
SEC Form 4 filed by Boyle Dana
4 - Liquidia Corp (0001819576) (Issuer)
10dINSIDER
SEC Form 4 filed by Kaseta Michael
4 - Liquidia Corp (0001819576) (Issuer)
10dINSIDER
SEC Form 4 filed by Krepp Sarah
4 - Liquidia Corp (0001819576) (Issuer)
10dINSIDER
SEC Form 4 filed by Saggar Rajeev
4 - Liquidia Corp (0001819576) (Issuer)
10dINSIDER
SEC Form 4 filed by Schundler Russell
4 - Liquidia Corp (0001819576) (Issuer)
10dINSIDER
SEC Form 4 filed by Jeffs Roger
4 - Liquidia Corp (0001819576) (Issuer)
10dSEC
SEC Form 144 filed by Liquidia Corporation
144 - Liquidia Corp (0001819576) (Subject)
11dINSIDER
SEC Form 4 filed by Jeffs Roger
4 - Liquidia Corp (0001819576) (Issuer)
11dINSIDER
SEC Form 4 filed by Kaseta Michael
4 - Liquidia Corp (0001819576) (Issuer)
14dSEC
SEC Form 144 filed by Liquidia Corporation
144 - Liquidia Corp (0001819576) (Subject)
14dSEC
SEC Form 144 filed by Liquidia Corporation
144 - Liquidia Corp (0001819576) (Subject)
15dSEC
SEC Form 144 filed by Liquidia Corporation
144 - Liquidia Corp (0001819576) (Subject)
15dSEC
SEC Form 144 filed by Liquidia Corporation
144 - Liquidia Corp (0001819576) (Subject)
17dPR
Liquidia Corporation to Participate in Upcoming Investor Conferences
MORRISVILLE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced it will participate in upcoming investor conferences. 2026 Raymond James Biotech Innovation SymposiumDate: Tuesday, April 14, 2026Location: Lotte New York Palace, New York, NYMichael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Business Officer, will participate in one-on-one investor meetings. 25th Annual Needham Virtual Healthcare ConferenceDate: Wednesday, April 15, 2026Location: Virtual EventIn a